- Home
- AUTL vs SOR Comparison
AUTL vs SOR Comparison
Compare AUTL & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.65
Company Overview
Basic Information| Metric | AUTL | SOR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United Kingdom | United States |
| Employees | 647 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 391.5M |
| IPO Year | 2025 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AUTL | SOR |
|---|---|---|
| Price | $1.65 | $48.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 11.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $670.78 | N/A |
| Revenue Next Year | $80.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $38.66 |
| 52 Week High | $2.70 | $50.41 |
Technical Indicators
Market Signals| Indicator | AUTL | SOR |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 46.58 |
| Support Level | $1.27 | $47.45 |
| Resistance Level | $1.74 | $48.16 |
| Average True Range (ATR) | 0.11 | 1.05 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 46.95 | 30.66 |
Price Performance
Historical Comparison AUTL
SOR
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.